Q-omics provides the consensus-scored UBE2V2 profile across patient tissues and cancer cell-line models. UBE2V2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, UBE2V2 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, UBE2V2 protein abundance shows 23,644 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, HNSC, and PDAC as cancer lineages where UBE2V2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2V2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2V2 survival associations across molecular data types. UBE2V2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2V2 RNA expression–survival associations across cancer types. High UBE2V2 expression shows unfavorable associations in UVM, HNSC, KIRP, KICH, ACC and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for UBE2V2 RNA expression.
This table summarizes UBE2V2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for UBE2V2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2V2 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, LUSC and LUAD. The HNSC box plot shows higher UBE2V2 RNA expression in tumor versus normal tissue (log2 FC = +1.028, t-test p < 0.001).
This table shows molecular features associated with UBE2V2 in patient tissues and cancer cell lines. In patient samples, UBE2V2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2V2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
